Annovis Bio receives ‘positive’ safety review by DSMB for buntanetap trial

Annovis Bio announced the positive safety review by the Data and Safety Monitoring Board for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease patients. The DSMB recommended that Annovis Bio continue the trial as originally designed. The feedback from the DSMB was: no drug-related SAEs (Serious Adverse Events); each AE (Adverse Event): less than 5 percent; very low dropout rate: 4.7 percent. “The findings from the DSMB are yet another positive affirmation for the direction we are taking in our research”, said Maria Maccecchini, Ph.D., CEO of Annovis. “We believe they are an important step along the way to potentially treating Alzheimer’s Disease.” Annovis initiated the trial of buntanetap in late March 2023. The DSMB safety evaluation was set to occur when 90 patients completed 6 weeks of treatment. When the DSMB was convened on October 18, 2023, the data from a total of 107 patients was evaluated.